International Union of Pharmacology. XXXV. The Glucagon Receptor Family

Pharmacological Reviews - Tập 55 Số 1 - Trang 167-194 - 2003
Kelly E. Mayo1,2,3,4,5,6, Laurence J. Miller1,2,3,4,5,6, D. Bataille1,2,3,4,5,6, Stéphane Dalle1,2,3,4,5,6, Burkhard Göke1,2,3,4,5,6, Bernard Thorens1,2,3,4,5,6, Daniel J. Drucker1,2,3,4,5,6
11Department of Biochemistry, Molecular Biology and Cell Biology, Northwestern University, Evanston, Illinois (K.E.M.)
22Mayo Clinic and Foundation, Department of Molecular Pharmacology and Experimental Therapeutics, Rochester, Minnesota (L.J.M.)
33INSERM U 376, Montpellier, France (D.B., S.D.)
44Department of Medicine II, Grosshadern, Klinikum der Ludwig-Maximilians, University of Munich, Germany (B.G.)
55Institute of Pharmacology and Toxicology, University of Lausanne, Lausanne, Switzerland (B.T.)
66Banting and Best Diabetes Centre, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada (D.J.D.)

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1074/jbc.270.26.15853

10.1210/en.136.4.1572

10.1016/0006-8993(90)91670-C

10.1007/s00125-001-0719-z

10.1053/jpsu.2000.6861

10.1210/en.138.3.1058

10.1007/s001250051051

10.1124/mol.58.5.911

10.1083/jcb.69.2.455

10.1210/en.130.3.1097

10.1038/306084a0

Barragan, 1999, Neural contribution to the effect of glucagon-like peptide-1-(7–36) amide on arterial blood pressure in rats., Am J Physiol, 277, E784

Bataille D (1996a) Oxyntomodulin and its related peptides. in Glucagon III, ed Lefebvre PJ (Springer-Verlag, Berlin), pp 327–340.

Bataille D (1996b) Preproglucagon and its processing. in Glucagon III, ed Lefebvre PJ (Springer-Verlag, Berlin), pp 31–51.

Baum, 1962, Localization of glucagon in the alpha cells in the pancreatic islet by immunofluorescent techniques., Diabetes, 11, 371

Baumann, 1997, The Dwarfs of Sindh: severe growth hormone (GH) deficiency caused by a mutation in the GH-releasing hormone receptor gene., Acta Paediatr Suppl, 423, 33, 10.1111/j.1651-2227.1997.tb18366.x

Bayliss, 1902, On the causation of the so-called “peripheral reflex secretion” of the pancreas., Proc R Soc Lond Biol, 69, 352, 10.1098/rspl.1901.0119

10.1210/en.137.10.4130

10.1038/304368a0

10.1038/302716a0

Benjamin MA McKay DM Yang PC Cameron H Perdue MH (2000) Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 47:112–119.

10.1210/endo-123-1-661

10.1073/pnas.83.18.6854

10.1073/pnas.211278098

10.1210/en.140.9.3919

10.1210/en.143.4.1475

10.1210/en.141.3.1228

Boushey, 1999, Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis., Am J Physiol, 277, E937

Boushey, 2001, Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor., Cancer Res, 61, 687

10.1016/S0196-9781(98)00176-4

10.1210/en.137.5.2159

Bromer, 1956, The amino acid sequence of glucagon., J Am Chem Soc, 78, 3858, 10.1021/ja01596a084

Brown JC (1982) Gastric inhibitory polypeptide. Monographs in Endocrinology (Springer-Verlag, Heidelberg).

Brubaker, 1997, Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2., Am J Physiol, 272, E1050

10.2337/diab.46.9.1400

Buhl, 1988, Naturally occurring products of proglucagon 111–160 in the porcine and human small intestine., J Biol Chem, 263, 8621, 10.1016/S0021-9258(18)68350-4

10.1210/en.137.7.2968

10.1016/S0026-0495(99)90043-4

10.1016/0378-1119(95)00472-I

10.1111/j.1749-6632.1999.tb08510.x

10.1073/pnas.182433099

10.1007/BF00585347

10.1002/(SICI)1096-9136(199610)13:10<854::AID-DIA262>3.0.CO;2-E

10.1016/0196-9781(91)90103-V

Campbell, 1992, Evolution of the growth hormone-releasing factor (GRF) family of peptides., Growth Regul, 2, 175

Canonico, 1983, Human pancreatic GRF stimulates phosphatidylinositol labeling in cultured anterior pituitary cells., Am J Physiol, 245, E587

Carruthers, 1994, Synthesis and expression of a gene for the rat glucagon receptor. Replacement of an aspartic acid in the extracellular domain prevents glucagon binding., J Biol Chem, 269, 29321, 10.1016/S0021-9258(19)62047-8

10.1021/jm970618s

Chance, 1997, Prevention of parenteral nutrition-induced gut hyoplasia by coinfusion of glucagon-like peptide-2., Am J Physiol, 273, G559

10.1207/S15327914NC372_15

Cheeseman, 1996, The effect of gastric inhibitory polypeptide and glucagon like peptides on intestinal hexose transport., Am J Physiol, 271, G477

10.1016/1043-2760(94)P3080-Q

10.1007/s00441-001-0494-7

Chiba, 1989, Mechanism for increase of gastrin release by secretin in Zollinger-Ellison syndrome., Gastroenterology, 96, 1439, 10.1016/0016-5085(89)90510-6

10.1016/S0196-9781(96)00320-8

10.1006/bbrc.1995.1957

Christophe, 1996, Glucagon and its receptor in various tissues., Ann NY Acad Sci, 805, 31, 10.1111/j.1749-6632.1996.tb17471.x

Christopoulos A, Christopoulos G, Morfis M, Udawela M, Laburthe M, Couvineau A, Kuwasako K, Tilakaratne N, and Sexton PM (2002) Novel receptor partners and function of receptor activity modifying proteins.J Biol Chem epub ahead of print.

10.1210/en.131.6.2785

Claus TH Park CR Pilkis SJ (1983) Glucagon and gluconeogenesis. in Glucagon I, ed Lefebvre PJ (Springer-Verlag, Berlin), pp 315–360.

10.1067/mpd.2001.112474

Coy, 1996, Structural simplification of potent growth hormone-releasing hormone analogs: implications for other members of the VIP/GHRH/PACAP family., Ann NY Acad Sci, 805, 149, 10.1111/j.1749-6632.1996.tb17480.x

10.1074/jbc.274.27.19455

10.1021/bi000497p

10.1210/en.142.10.4244

10.2337/diabetes.51.2.406

10.1074/jbc.274.16.10869

10.1007/s001250050903

10.1210/me.12.5.750

10.1210/jc.81.9.3168

10.1016/S0167-5699(99)01486-3

Diamant B Picazo J (1983) Spasmolytic and clinical use of glucagon. in Glucagon II, ed Lefebvre PJ (Springer-Verlag, Berlin), pp 611–643.

10.1210/en.133.4.1907

Ding, 2002, Silencing of secretin receptor function by dimerization with a misspliced variant secretin receptor in ductal pancreatic adenocarcinoma., Cancer Res, 62, 5223

10.1053/gast.2002.31039

10.1074/jbc.274.27.19161

Dong, 2000, Dual contacts between peptide agonist ligands and the secretin receptor directly established by photoaffinity labeling., Ann NY Acad Sci, 921, 381, 10.1111/j.1749-6632.2000.tb07000.x

10.1074/jbc.274.2.903

10.1210/me.2002-0111

10.1210/en.142.10.4462

10.2337/diab.47.2.159

10.2174/1381612013397401

10.1210/jc.86.4.1759

10.1210/en.142.2.521

10.1053/gast.2002.34757

10.1210/me.2002-0306

Drucker, 1988, Glucagon gene expression in vertebrate brain., J Biol Chem, 263, 13475, 10.1016/S0021-9258(18)68261-4

Drucker, 1999, Biologic properties and therapeutic potential of glucagon-like peptide-2., J Parenter Enteral Nutr, 23 (Suppl 5), S98, 10.1177/014860719902300524

Drucker, 1997, Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2., Am J Physiol, 273, G1252

10.1073/pnas.93.15.7911

10.1073/pnas.84.10.3434

10.1038/nbt0797-673

Drucker, 1999, Human [Gly2]-GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis., Am J Physiol, 276, G79

10.1016/S0303-7207(98)00096-3

10.2337/diab.15.8.555

10.1210/jcem-37-5-826

Eaton RP (1977) Glucagon and lipoprotein regulation in man. in Glucagon: Its Role in Physiology and Clinical Medicine, eds Foa PP Bajaj JS Foa NL (Springer-Verlag, Berlin), p 553.

Ebert, 1987, Gastrointestinal peptides and insulin secretion., Diabetes Metab Rev, 3, 1, 10.1002/dmr.5610030101

10.1210/jc.87.3.1282

10.1074/jbc.M103023200

10.1074/jbc.M205055200

Eicher, 1976, Inherited ateliotic dwarfism in mice. Characteristics of the mutation, little, on chromosome 6., J Hered, 67, 87, 10.1093/oxfordjournals.jhered.a108682

10.1530/acta.0.1120345

Farah AE (1983) Glucagon and the heart. in Glucagon II, ed Lefebvre PJ (Springer-Verlag, Berlin), pp 553–609.

10.1016/0196-9781(95)00090-7

10.1210/edrv-16-3-390

10.1016/0014-5793(91)80182-3

10.1210/en.130.1.159

10.1097/00006676-199508000-00014

10.1016/0303-7207(90)90146-Y

10.1172/JCI114049

10.1210/edrv-7-3-223

Frohman, 1981, Ectopic production of growth hormone-releasing factor by carcinoid and pancreatic islet tumors associated with acromegaly., Prog Clin Biol Res, 74, 259

10.1210/mend-3-10-1529

10.1016/S0014-5793(98)01116-8

Gardner, 1976, Interaction of peptides related to secretin with hormone receptors on pancreatic acinar cells., Gastroenterology, 71, 965, 10.1016/S0016-5085(76)80043-1

10.1006/bbrc.2002.6364

Gaylinn, 1999, Molecular and cell biology of the growth hormone-releasing hormone receptor., Growth Horm IGF Res, 9 (Suppl A), 37, 10.1016/S1096-6374(99)80008-2

10.1210/en.140.11.5066

10.1210/me.7.1.77

10.1210/en.135.3.950

10.1006/geno.1994.1045

10.1016/S0167-0115(97)00009-8

10.1073/pnas.0237106100

10.1210/en.138.6.2640

10.1073/pnas.81.5.1553

10.1210/en.140.6.2836

10.1038/ng0793-227

10.1677/jme.0.0020093

10.1677/joe.0.1160357

Goke, 1993, Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like peptide 1-(7–36)-amide receptor of insulin-secreting β-cells., J Biol Chem, 268, 19650, 10.1016/S0021-9258(19)36565-2

10.1016/0196-9781(94)90095-7

10.1111/j.1460-9568.1995.tb00650.x

10.1016/0014-5793(92)80852-8

Goke, 1989, Signal transmission after GLP-1(7–36)amide binding in RINm5F cells., Am J Physiol, 257, G397

10.1006/bbrc.1993.2226

10.2337/diab.44.10.1202

Gros, 1992, Characterization of high affinity receptors for glucagon-like peptide-1 (7–36)amide on a somatostatin-secreting cell line., Biomed Res, 13, 143

10.1126/science.6812220

Gutzwiller, 1999, Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2., Am J Physiol, 276, R1541

Haffar, 1991, Reduced peptide bond pseudopeptide analogues of secretin. A new class of secretin receptor antagonists., J Biol Chem, 266, 316, 10.1016/S0021-9258(18)52437-6

10.1038/ng0395-299

10.1016/S0167-4838(00)00270-3

10.1210/jc.2002-020347

10.1038/315413a0

10.1016/0014-5793(88)80297-7

Hansen, 2001, The growth hormone-releasing hormone receptor: desensitisation following short-term agonist exposure., Pharmacol Toxicol, 88, 81, 10.1034/j.1600-0773.2001.d01-87.x

Hansen, 1998, Glucagon-mediated Ca2+ signaling in BHK cells expressing cloned human glucagon receptors., Am J Physiol, 274, C1552, 10.1152/ajpcell.1998.274.6.C1552

Harmar, 2001, Family-B G-protein-coupled receptors., Genome Biol, 2, REVIEWS3013, 10.1186/gb-2001-2-12-reviews3013

10.1210/jc.85.8.2884

10.1016/S0167-0115(02)00013-7

10.1210/en.141.11.4013

10.1210/jc.80.10.2933

10.1006/abbi.2000.2208

10.1016/0196-9781(95)02026-8

10.2337/diab.46.5.785

10.2337/diabetes.51.3.652

10.1016/S0167-4838(01)00181-9

10.1016/S0014-5793(99)00864-9

10.1210/endo-122-6-2927

10.1007/s001250050779

10.1074/jbc.271.25.14944

10.1074/jbc.270.24.14394

10.1074/jbc.271.38.23566

10.1074/jbc.270.30.17749

10.1074/jbc.274.20.14147

10.1016/0014-5793(84)81245-4

10.1073/pnas.81.14.4368

Horikawa, 2002, [Isolated GH deficiency due to inactivating mutation of GHRH receptor]., Nippon Rinsho, 60, 297

10.1210/en.142.6.2660

10.1210/en.137.6.2642

10.1016/0143-4179(93)90062-F

10.1007/s001250051484

10.1074/jbc.274.17.12108

10.1016/S0167-0115(00)00232-9

Isenberg, 1972, Unusual effect of secretin on serum gastrin, serum calcium and gastric acid secretion in a patient with suspected Zollinger-Ellison syndrome., Gastroenterology, 62, 626, 10.1016/S0016-5085(72)80048-9

Ishihara, 1991, Molecular cloning and expression of a cDNA encoding the secretin receptor., EMBO (Eur Mol Biol Organ) J, 10, 1635, 10.1002/j.1460-2075.1991.tb07686.x

Iyengar, 1984, Structural analysis of the hepatic glucagon receptor. Identification of a guanine nucleotide-sensitive hormone-binding region., J Biol Chem, 259, 5222, 10.1016/S0021-9258(17)42978-4

10.1126/science.8384375

10.1053/gast.2001.22555

10.1002/cne.902710405

10.1016/S0378-1119(99)00392-3

10.2337/diabetes.51.2.424

10.3109/10799899709036610

10.1111/j.1469-7793.2001.0375c.xd

10.1074/jbc.M108378200

10.1385/JMN:18:1-2:07

10.1016/S0022-3468(99)90221-X

10.1007/BF00400630

10.1210/jcem-15-9-1089

10.1210/er.20.6.876

10.1210/en.136.8.3585

Kimball, 1923, Aqueous extracts of pancreas., J Biol Chem, 58, 337, 10.1016/S0021-9258(18)85474-6

10.1073/pnas.97.2.532

10.2337/diab.44.1.16

10.1073/pnas.87.6.2299

10.1073/pnas.88.12.5335

10.1677/joe.0.152R013

10.1210/en.137.4.1326

Kubiak TM Friedman AR Moseley WM (1996) Synthetic analogs of growth hormone releasing factor (GHRF) with improved pharmaceutical properties. in Growth Hormone Secretagogues, eds Berc BB Walker RF (Springer Publishing, New York), pp 31–52.

10.2337/diab.45.12.1701

10.1006/bbrc.1997.6743

10.1016/S0960-894X(01)00766-1

10.1159/000127075

10.1016/0006-291X(84)91647-4

10.1016/S0196-9781(97)00001-6

10.1055/s-0029-1211301

10.1016/S0306-4522(96)00434-4

Lasko, 2001, Differential GH-releasing hormone regulation of GHRH receptor mRNA expression in the rat pituitary., Am J Physiol Endocrinol Metab, 280, E626, 10.1152/ajpendo.2001.280.4.E626

10.1210/jc.86.8.3989

Leiter AB Chey WY Kopin AS (1994) Secretin. in Gut Peptides: Biochemistry and Physiology, eds Walsh JH Dockray GJ (Raven Press, New York), pp 147–174.

10.1074/jbc.M209423200

10.1210/me.2002-0084

10.1038/360765a0

10.1038/364208a0

10.1021/jm000547o

10.1016/S0960-894X(01)00819-8

Ling, 1984, Synthesis and in vitro bioactivity of C-terminal deleted analogs of human growth hormone-releasing factor., Biochem Biophys Res Commun, 123, 854, 10.1016/0006-291X(84)90309-7

10.1073/pnas.81.14.4302

10.1007/s004280000374

10.1016/0378-1119(94)90545-2

10.1073/pnas.80.18.5485

Lotersztajn, 1990, Glucagon-(19–29) exerts a biphasic action on the liver plasma membrane Ca2+ pump which is mediated by G proteins., J Biol Chem, 265, 9876, 10.1016/S0021-9258(19)38753-8

10.1074/jbc.M009382200

10.1210/en.141.11.4194

10.1210/en.132.1.94

10.1073/pnas.79.2.345

10.1210/endo-128-1-570

Lutz, 1993, Control of cholecystokinin receptor dephosphorylation in pancreatic acinar cells., J Biol Chem, 268, 12136, 10.1016/S0021-9258(19)50318-0

10.2337/diabetes.50.5.1004

10.1210/en.141.2.752

10.1006/bbrc.1994.1046

10.1021/jm9810304

10.1038/325620a0

10.1210/endo-126-1-151

10.1006/geno.1995.9922

10.1210/en.136.9.4147

10.1210/me.6.10.1734

10.1038/314464a0

Mayo, 1995, Growth hormone-releasing hormone: synthesis and signaling., Recent Prog Horm Res, 50, 35

10.1210/mend-2-7-606

Mayo, 2000, Regulation of the pituitary somatotroph cell by GHRH and its receptor., Recent Prog Horm Res, 55, 237

Mayo, 1996, The growth-hormone-releasing hormone receptor: signal transduction, gene expression and physiological function in growth regulation., Ann NY Acad Sci, 805, 184, 10.1111/j.1749-6632.1996.tb17483.x

10.1038/306086a0

10.1016/S0196-9781(99)00011-X

10.1210/en.140.1.398

10.2337/diabetes.50.11.2497

Mentlein, 1993, Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum., Eur J Biochem, 214, 829, 10.1111/j.1432-1033.1993.tb17986.x

10.1006/geno.1994.1179

10.1002/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5

10.1210/endo-114-4-1082

Merimee TJ (1983) Glucagon and growth hormone. in Glucagon II, ed Lefebvre PJ (Springer-Verlag, Berlin), pp 545–551.

10.1006/bbrc.1995.2880

10.1006/bbrc.1996.1068

10.1210/en.140.9.4152

10.1210/en.138.6.2458

10.1038/nm727

10.1073/pnas.96.26.14843

10.2337/diabetes.51.3.669

10.2337/diab.47.1.66

10.2337/diab.45.2.257

Mojsov, 1986, Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing., J Biol Chem, 261, 11880, 10.1016/S0021-9258(18)67324-7

10.1677/jme.0.0250157

10.1002/(SICI)1097-4652(199709)172:3<275::AID-JCP1>3.0.CO;2-L

10.1159/000054467

Morris, 1996, Hypothesis: glucagon receptor glycine to serine missense mutation contributes to one in 20 cases of essential hypertension., Clin Exp Pharmacol Physiol, 23, 1035, 10.1111/j.1440-1681.1996.tb01164.x

Motomura, 1998, Inhibition of signal transduction by a splice variant of the growth hormone-releasing hormone receptor expressed in human pituitary adenomas., Metab Clin Exp, 47, 804, 10.1016/S0026-0495(98)90116-0

10.2337/diacare.8.3.268

10.1073/pnas.96.4.1569

Mutt V (1980) Secretin: isolation, structure and functions. in Gastrointestinal Hormones, ed Glass GBJ (Raven Press, New York), pp 85–126.

Mutt, 1966, Structure of porcine secretin I., Biochem J, 4, 2358, 10.1021/bi00887a014

10.1172/JCI116186

10.1210/jc.83.2.432

10.1016/S0014-5793(99)01112-6

10.1210/en.140.12.5817

10.1210/en.143.4.1318

O'Harte, 1999, NH2-terminally modified gastric inhibitory polypeptide exhibits amino- peptidase resistance and enhanced antihyperglycemic activity., Diabetes, 48, 758, 10.2337/diabetes.48.4.758

10.1677/joe.0.1650639

10.1210/endo-126-1-488

10.1006/bbrc.1995.2728

10.1210/endo-119-4-1467

10.2337/diab.42.5.658

10.1038/35041046

Ozcelebi, 1995, Agonist-stimulated phosphorylation of the carboxyl-terminal tail of the secretin receptor., Mol Pharmacol, 48, 818

Park, 2000, Cross-chimeric analysis of selectivity of secretin and VPAC(1) receptor activation., J Pharmacol Exp Ther, 295, 682

10.1006/bbrc.2001.6265

Parker, 1998, Structure-function analysis of a series of glucagon-like peptide-1 analogs., J Pept Res, 52, 398, 10.1111/j.1399-3011.1998.tb00664.x

10.1074/jbc.271.38.23222

10.1210/en.142.3.1117

10.1124/jpet.102.037481

10.1124/jpet.300.3.958

10.1007/s001250100006

10.1210/me.12.2.233

10.1210/en.141.6.2113

10.1074/jbc.274.12.8181

10.1016/S0022-3468(00)90040-X

10.1053/jpsu.2001.22284

10.1210/en.140.4.1752

10.2337/diacare.24.9.1640

10.1073/pnas.180313297

10.1056/NEJM199210013271403

10.1016/0014-5793(90)80292-Q

10.1016/0014-5793(91)80303-K

10.1677/joe.0.1590093

10.1038/300276a0

10.1210/endo-117-5-1759

Rodbell, 1971, The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. V. An obligatory role of guanylnucleotides in glucagon action., J Biol Chem, 246, 1877, 10.1016/S0021-9258(18)62390-7

Rodbell, 1971, The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. 3. Binding of glucagon: method of assay and specificity., J Biol Chem, 246, 1861, 10.1016/S0021-9258(18)62388-9

10.1210/en.140.1.22

10.1210/me.16.3.450

10.1210/jc.86.1.273

10.1210/jc.84.3.917

10.1046/j.1365-2265.2001.01213.x

10.2337/diab.15.12.855

10.2337/diabetes.48.5.1045

Sato, 1997, Gene regulation of growth hormone-releasing hormone and its receptor., Endocr J, 44, 765, 10.1507/endocrj.44.765

10.1002/cne.902370108

10.1016/S1043-2760(99)00209-X

Schirra, 1997, Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility and pancreatic function in men., Proc Assoc Am Physicians, 109, 84

10.1172/JCI1349

Schmidtler, 1994, Rat parietal cell receptors for GLP-1-(7–36) amide: Northern blot, cross-linking and radioligand binding., Am J Physiol, 267, G423

Scott, 1998, GLP-2 augments the adaptive response to massive intestinal resection in rat., Am J Physiol, 275, G911

10.1038/nm1196-1254

10.2337/diabetes.49.9.1552

10.1210/en.141.2.473

10.1038/313487a0

10.1074/jbc.273.12.6756

10.1210/endo-121-3-1076

10.1097/00006676-200205000-00010

10.1210/en.137.11.5159

10.1016/S0167-0115(98)00155-4

Sivarajah, 2001, Evolution of receptors for proglucagon-derived peptides: isolation of frog glucagon receptors., Comp Biochem Physiol Part B Comp Biochem Mol Biol, 128, 517, 10.1016/S1096-4959(00)00355-9

10.1038/303532a0

Stalmans W (1983) Glucagon and liver glycogen metabolism. in Glucagon I, ed Lefebvre PJ (Springer-Verlag, Berlin), pp 291–314.

10.1210/endo-125-5-2710

Steinberg, 1959, Direct effect of glucagon on release of unesterified fatty acids (UFA) from adipose tissue., Clin Res, 7, 250

Stephanou, 1991, Production of a growth hormone-releasing hormone-like peptide and its mRNA by human lymphocytes., Neuroendocrinology, 53, 628

10.2337/diab.42.8.1215

10.2337/diabetes.49.5.741

10.1210/mend-3-11-1693

Sutherland, 1950, The effect of the hyperglycemic factor of the pancreas and of epinephrine on glycogenolysis., Recent Prog Horm Res, 5, 441

10.1006/bbrc.1993.1392

10.1016/S0196-9781(98)00040-0

10.1016/0303-7207(94)90162-7

10.1210/en.136.10.4721

10.1210/jc.80.8.2381

10.1038/77535

10.1073/pnas.89.18.8641

10.2337/diab.42.11.1678

Thorens B Widmann C (1996) Structure and function of the glucagon-like peptide-1 receptor. in Handbook of Experimental Pharmacology Glucagon III, ed Lefebvre PJ (Springer-Verlag, Berlin), pp 255–273.

Thorner, 1982, Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor., J Clin Investig, 70, 965, 10.1172/JCI110708

10.1016/S0196-9781(00)00305-3

10.1016/S0167-0115(01)00316-0

10.1074/jbc.M106692200

10.1073/pnas.84.10.3146

10.1210/me.15.9.1559

Tsai, 1997, Intestinal growth-promoting properties of glucagon-like peptide 2 in mice., Am J Physiol, 273, E77

Tsai, 1997, Biological determinants of intestinotrophic properties of GLP-2 in vivo., Am J Physiol, 272, G662

10.1073/pnas.90.5.1992

10.1172/JCI119060

10.1006/bbrc.1997.6231

10.1016/S0303-7207(98)00061-6

10.1038/379069a0

10.1016/S0016-5085(98)70491-3

10.1016/0016-5085(93)90162-6

10.1001/archinte.1969.00300130043007

10.1074/jbc.270.46.27720

10.1006/abbi.1993.1103

Unson, 1991, Position 9 replacement analogs of glucagon uncouple biological activity and receptor binding., J Biol Chem, 266, 2763, 10.1016/S0021-9258(18)49911-5

10.1073/pnas.91.2.454

10.1021/bi025711j

10.1074/jbc.M002093200

10.1210/en.133.6.2861

10.1016/0014-5793(90)80173-G

10.1210/en.132.1.75

10.1016/0014-5793(94)00553-2

10.1073/pnas.96.2.692

Vaudry, 2000, Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions., Pharmacol Rev, 52, 269

10.1016/0006-291X(85)90567-4

10.1210/jc.86.9.4382

10.1006/bbrc.1995.1895

10.2337/diabetes.50.3.609

10.1007/BF00354940

10.1038/ng0196-88

10.1038/323068a0

10.1016/0014-5793(94)01430-9

10.1074/jbc.274.35.24593

10.1210/en.136.10.4629

10.1210/me.11.8.1094

10.1210/en.140.2.624

10.1016/S0196-9781(96)00321-X

Xiao, 2000, Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease., Am J Physiol, 278, R1057

10.1016/S0016-5085(99)70555-X

10.1021/bi0014498

10.1677/jme.0.0250321

10.1210/en.133.4.1685

10.1006/geno.1995.9937

10.1172/JCI200215595

Yamato, 1997, Tissue-specific and glucose-dependent expression of receptor genes for glucagon and glucagon-like peptide-1 (GLP-1)., Horm Metab Res, 29, 56, 10.1055/s-2007-978985

10.1006/bbrc.1994.2844

10.1016/S0024-3205(99)00314-8

10.1074/jbc.M005510200

10.1074/jbc.M201358200

10.1053/gast.2000.16489

10.1074/jbc.274.43.30459

10.1016/S0140-6736(02)07952-7

10.1073/pnas.91.25.12298

10.1385/ENDO:12:3:257

10.1677/jme.0.0210363

10.1016/S1367-5931(00)00103-4

10.1016/S0196-9781(00)00287-4

10.1073/pnas.162352599